Unlocking the Mystery of Fatigue in PBC: Elafibranor's Surprising Impact
Could a drug designed for liver disease hold the key to alleviating the debilitating fatigue experienced by patients with primary biliary cholangitis (PBC)? Recent research reveals a fascinating connection between elafibranor, a PPAR α/δ agonist, and the intricate pathways of fatigue and mitochondrial function.
A groundbreaking study presented at the American Association for the Liver Diseases (AASLD) Liver Meeting 2025 by Dr. Mark Swain and colleagues sheds light on the relationship between elafibranor and fatigue-related proteins. They discovered that elafibranor treatment resulted in altered expression of 10 proteins associated with fatigue or mitochondrial function, and these changes were significantly correlated with each other and with improvements in fatigue symptoms. But here's where it gets intriguing: these correlations suggest that elafibranor's PPARα/δ agonism may positively influence fatigue-associated pathways linked to mitochondrial function.
Fatigue is a common and debilitating symptom for PBC patients, yet its underlying mechanisms remain elusive. Elafibranor, approved for PBC second-line treatment, has demonstrated clinically significant fatigue improvements. Building on previous research from the European Association for the Liver (EASL) Congress 2025, which identified 10 proteins affected by elafibranor treatment, the AASLD study delved deeper into the relationship between these proteins and fatigue severity.
The researchers analyzed serum samples from patients in the phase 3 ELATIVE trial, using the Olink® Explore HT proteomic panel. They found significant correlations between changes in protein expression and fatigue severity, particularly in patients with baseline moderate-to-severe fatigue. Interestingly, in these patients, elafibranor treatment led to moderate-to-strong correlations between expression changes of most proteins and fatigue improvement.
And this is the part most people miss: the study suggests that elafibranor's impact on fatigue-associated pathways may be linked to its effect on mitochondrial function. This finding opens up exciting possibilities for further research into the role of PPARα/δ agonism in fatigue improvement, potentially leading to new therapeutic strategies for PBC patients.
But is elafibranor the silver bullet for PBC-related fatigue? While the study's results are promising, more research is needed to fully understand the complex interplay between elafibranor, fatigue pathways, and mitochondrial function. The authors invite further investigation into the mechanistic contribution of PPARα/δ agonism to fatigue improvement, which could revolutionize our approach to managing this challenging symptom in PBC patients.
What do you think? Are we on the cusp of a breakthrough in PBC treatment, or is there more to uncover? Share your thoughts in the comments below!
